Breaking News Instant updates and real-time market news.

PVH

PVH Corp.

$98.85

-3.75 (-3.66%)

, SNX

Synnex

$86.80

1.55 (1.82%)

18:51
01/10/19
01/10
18:51
01/10/19
18:51

Fly Intel: After Hours Movers

UP AFTER EARNINGS: PVH (PVH) up 5.1% after raising Q4 EPS outlook... Synnex (SNX) up 4.8%. ALSO HIGHER: Embraer (ERJ) up 3.8% after receiving Brazil government approval for Boeing merger... Ocular Therapeutix (OCUL) up 2.5% after submitting Dextenza NDA to FDA... Netflix (NFLX) up 1.7% after upgrade to Buy at UBS... Lennar (LEN) up 1.5% after announcing $1B stock buyback... Glu Mobile (GLUU) up 1.0% after being initiated at Overweight at Stephens. LOWER: Activision Blizzard (ATVI) down 6.7% after disclosing Bungie to assume publishing rights for Destiny franchise... Seadrill (SDLP) down 1.6% after resignation of CEO... Urban Outfitters (URBN) down 1.4% after holiday sales update. Movers as of 18:30ET.

PVH

PVH Corp.

$98.85

-3.75 (-3.66%)

SNX

Synnex

$86.80

1.55 (1.82%)

ERJ

Embraer

$22.63

-0.47 (-2.03%)

OCUL

Ocular Therapeutix

$4.00

-0.15 (-3.61%)

NFLX

Netflix

$324.77

4.81 (1.50%)

LEN

Lennar

$45.17

-1.14 (-2.46%)

GLUU

Glu Mobile

$9.10

0.21 (2.36%)

ATVI

Activision Blizzard

$51.35

0.52 (1.02%)

SDLP

Seadrill Partners

$1.88

-0.07 (-3.59%)

URBN

Urban Outfitters

$32.56

-1.2 (-3.55%)

  • 10

    Jan

  • 14

    Jan

  • 14

    Jan

  • 15

    Jan

  • 12

    Feb

PVH PVH Corp.
$98.85

-3.75 (-3.66%)

01/07/19
UBSW
01/07/19
UPGRADE
Target $145
UBSW
Buy
PVH Corp. upgraded to Buy from Neutral at UBS
UBS analyst Jay Sole upgraded PVH to Buy from Neutral citing the underlying strength in its Calvin Klein brand. He believes the company has fixed its missteps and is not being credited for it while estimating wholesale order growth will accelerate quarter-over-quarter. Sole said he sees a solid opportunity to buy the stock at an attractive valuation. Sole lowered his price target to $145 from $170 on PVH Corp. shares.
01/09/19
RBCM
01/09/19
INITIATION
Target $122
RBCM
Outperform
PVH Corp initiated with an Outperform at RBC Capital
RBC Capital analyst Brian Tunick initiated PVH (PVH) with an Outperform rating and a price target of $122, citing the company's "strong brands" and Calvin Klein margin recovery. The analyst further notes that since valuation on PVH stock has come in by 4- to 6-times over the past few months, risk reward on the stock has turned more favorable at current levels. Tunick expects the company's best-in-class initiatives to adapt to "new retail" thanks to its Amazon (AMZN) partnerships, social media presence and celebrity collaborations, winning market share and building increased "relevance" with younger consumers.
01/02/19
WELS
01/02/19
NO CHANGE
Target $125
WELS
Outperform
PVH Corp. price target lowered to $125 from $140 at Wells Fargo
Wells Fargo analyst Ike Boruchow lowered his price target for PVH Corp. to $125 from $140, while reiterating an Outperform rating on the shares. In a research note titled "2019 Retail Outlook report," the analyst says he believes Holiday reads likely slowed post Black Friday, Multinational brands struggled relative to retailers the past several months as concerns around Europe weakness, China uncertainty, a slowdown in tourism and FX pressures are growing, e-commerce meaningfully underperformed Brick and Mortar retail in 2018 as inflated multiples have been hit hard in the face of a painful tech ''unwind'' and choppier fundamentals, 2019 is likely to be worse than 2018 for the space, and Leases are coming onto retailers' balance sheets in 2019, making for worse capital structure optics.
12/31/18
PIPR
12/31/18
NO CHANGE
Target $30
PIPR
Overweight
Piper favors Nike, Under Armour, Ulta, Crocs and Funko as 2019 brand ideas
Piper Jaffray analyst Erinn Murphy lowered her price targets across the Global Lifestyle Brands group to reflect the recent market volatility. The analyst, however, feels good about the Holiday while remaining "wary on multi-brand retailers on a longer-term basis." Murphy favors Nike (NKE), Under Armour (UAA), Ulta Beauty (ULTA), Crocs (CROX) and Funko (FNKO) as 2019 ideas. She sees Under Armour as one of the better names to own into 2019 with "what still appears to be a healthy amount of skepticism around the stock." Management's 2019 targets will ultimately prove conservative and upside should continue throughout the year, Murphy tells investors in a research note. The analyst keeps an Overweight rating on Under Armour but lowered her price target for the shares to $30 from $32. She cut targets on 15 names in the Global Lifestyle Brands space, including Underweight-rated e.l.f. Beauty (ELF) to $8 from $10, Overweight-rated G-III Apparel (GIII) to $40 from $50, Overweight-rated PVH Corp. (PVH) to $140 from $150, Overweight-rated Ulta Beauty to $295 from $320 and Overweight-rated VF Corp. (VFC) to $91 from $104.
SNX Synnex
$86.80

1.55 (1.82%)

10/04/18
NEED
10/04/18
UPGRADE
Target $135
NEED
Strong Buy
Synnex upgraded to Strong Buy at Needham after another 'solid' quarter
As reported earlier, Needham analyst Sean Hannon upgraded Synnex to Strong Buy from Buy with a price target of $135 after its "solid" earnings result in Q3. The analyst cites the company's business becoming "more diversified, experiencing healthy fundamental demand, and expanding its structural margin profile". Hannon further notes the Street being too focused on the margin pressure of Synnex's Hyve business while missing a "bigger story of strong profit growth" while also pointing to the valuation on the stock reaching "trough levels" of 6.8-times forward earnings based on the aftermarket price yesterday.
10/04/18
RHCO
10/04/18
NO CHANGE
Target $100
RHCO
Buy
Synnex price target lowered to $100 from $125 at SunTrust
SunTrust analyst Frank Atkins lowered his price target on Synnex (SNX) to $100, saying that while Q3 earnings topped expectations, the outlook for Q4 was disappointing. The analyst also recommends that investors buy the shares on weakness, anticipating margin expansion in FY19 to drive multiples while the company also allocates some of the cashflows to debt payment. Atkins further sees reduced revenue volatility coming from Synnex's acquisition of Convergys (CVG).
10/04/18
10/04/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. National Storage (NSA) upgraded to Buy from Hold at Jefferies with analyst George Hoglund saying he believes the recent weakness in the shares is overdone and presents a buying opportunity. 2. Cummins (CMI) upgraded to Overweight from Neutral at Piper Jaffray with analyst Alexander Potter saying his deep-dive analysis illuminates the likelihood of upside versus consensus estimates in the coming years. 3. Synnex (SNX) upgraded to Strong Buy from Buy at Needham with analyst Sean Hannon citing the company's business becoming "more diversified, experiencing healthy fundamental demand, and expanding its structural margin profile." 4. Cloudera (CLDR) upgraded to Buy from Neutral at DA Davidson and Nomura Instinet. 5. Washington Trust (WASH) upgraded to Buy from Hold at Sandler O'Neill withh analyst Mark Fitzgibbon saying management went out of their way to focus on their organic growth and "made a compelling argument that there is a dearth of good mid-size banks in New England." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/04/18
NEED
10/04/18
UPGRADE
NEED
Strong Buy
Synnex upgraded to Strong Buy from Buy at Needham
ERJ Embraer
$22.63

-0.47 (-2.03%)

09/26/18
BRSE
09/26/18
UPGRADE
BRSE
Outperform
Embraer upgraded to Outperform from Neutral at Bradesco
Bradesco analyst Victor Mizusaki upgraded Embraer to Outperform and raised its price target to $28 from $23 citing attractive risk/reward.
10/19/18
10/19/18
NO CHANGE

Embraer delivers 15 commercial and 24 executive jets in Q3
Embraer delivered 15 jets to the commercial aviation market and 24 business jets in Q3, being 17 light jets and 7 large jets. On September 30, Embraer's firm order backlog totaled $13.6B. In the commercial aviation market, Embraer forecasted in its Market Outlook a demand for 10,550 new aircraft with up to 150 seats worldwide over the next 20 years. The in-service fleet is set to increase to 16,000 aircraft, up from the 9,000 aircraft currently in operation. Market growth will drive 65% of this demand, while the remaining 35% of the projected demand will be to replace ageing aircraft. Embraer and Helvetic Airways signed a contract for a firm order of 12 E190-E2 jets during Q3. The contract also includes purchase rights for another 12 E190-E2 aircraft. Deliveries should occur between the end of 2019 and 2021. United Airlines made a firm order for 25 E175 jets in a 70-seat configuration. Deliveries will begin in 2Q19. Embraer also signed a contract with an undisclosed customer in Q3 for up to five E195-E2s, being three firm orders and two purchase rights. In addition, the company continues to work on finalizing its recent LoI for 100 E175 aircraft for Republic Airways, with the expectation that a significant portion of these jets should enter the company's backlog by the end of 2018. A total of 134 jets were removed from Embraer's backlog in Q3.
08/24/18
08/24/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Netflix (NFLX) upgraded to Buy from Hold at SunTrust with analyst Matthew Thornton saying the pullback after the Q2 subscriber miss was driven in part by the interest in World Cup viewing. 2. Sanderson Farms (SAFM) upgraded to Overweight from Equal Weight at Stephens with analyst Farha Aslam citing the company's Q3 results and saying she believes weak chicken fundamentals are now priced into the shares. 3. Children's Place (PLCE) upgraded to Buy from Neutral at Monness Crespi analyst Jim Chartier saying the modest sell-off in shares following strong Q2 results provides a buying opportunity. 4. Mylan (MYL) upgraded to Outperform from In Line at Evercore ISI. 5. Embraer (ERJ) upgraded to Hold from Underperform at Santander. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/18/18
COWN
12/18/18
NO CHANGE
Target $445
COWN
Outperform
Cowen says Boeing dividend hike topped expectation
Cowen analyst Cai von Rumohr said Boeing (BA) remains a top pick given its estimated 2019 free cash flow yield and peer high dividend. He noted that the company's dividend hike announcement topped his estimate and he said the finalized joint venture announcement with Embraer (ERJ) offers large, value accretive cost/revenue synergies. Rumohr reiterated his Outperform rating and $445 price target on Boeing shares.
OCUL Ocular Therapeutix
$4.00

-0.15 (-3.61%)

01/04/19
PIPR
01/04/19
NO CHANGE
Target $14
PIPR
Overweight
Piper sees 'significant share appreciation' potential for Ocular Therapeutix
Ocular Therapeutix expects top-line data from OTX-TP's first Phase III glaucoma study in the first half of 2019, Piper Jaffray analyst Joseph Catanzaro tells investors in a research note. The analyst believes investors have discounted this program based on mixed Phase I/II data that utilized different formulations and study designs. However, he thinks the Phase III design gives OTX-TP the best chance at demonstrating clinical efficacy in this setting. A successful outcome will be statistically significant IOP-reductions over placebo at all time points and importantly, at least a 5 mm Hg reduction in IOP from baseline at 6 of the 9 time points, Catanzaro contends, citing his review of literature and a survey of ophthalmologists. He believes such an outcome would represent "another successful application of the hydrogel platform and drive significant share appreciation." The analyst has an Overweight rating on Ocular Therapeutix with a $14 price target.
12/04/18
HCWC
12/04/18
NO CHANGE
Target $12
HCWC
Buy
Ocular Therapeutix price target raised to $12 from $10 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised his price target for Ocular Therapeutix to $12 after the FDA approved Dextenza for intracanalicular use for the treatment of ocular pain following ophthalmic surgery. The analyst believes the news should bolster confidence in the company among investors. The approval not only validates Ocular's hydrogel drug delivery platform, but endorses the incumbent management team's execution and accountability, Selvaraju tells investors in a research note. He reiterates a Buy rating on the name.
12/03/18
PIPR
12/03/18
NO CHANGE
Target $14
PIPR
Overweight
Piper calls Dextenza approval 'transformational' for Ocular Therapeutix
Piper Jaffray analyst Joseph Catanzaro views the FDA approval of Dextenza for the treatment of ocular pain following ophthalmic surgery as "transformational" for Ocular Therapeutix. The news lifts a "significant overhang" on the stock that has persisted for the last couple of years and allows Ocular to realize the full potential of the entire hydrogel platform. Notably, the approval came with no post-approval commitments outside of doing a pediatric study, Catanzaro tells investors in a research note. The analyst says that while meaningful sales are not expected until pass-through reimbursement is established, he currently model Dextenza sales in the post-cataract setting growing to $250M-plus by 2025. He keeps an Overweight rating on Ocular Therapeutix with a $14 price target. The stock in morning trading is down 5%, or 36c, to $6.30.
12/03/18
CANT
12/03/18
NO CHANGE
Target $24
CANT
Overweight
Cantor Fitzgerald raises Ocular Therapeutix price target to $24 after approval
After Ocular Therapeutix announced that Dextenza has been approved by the FDA for the treatment of ocular pain following ophthalmic surgery approximately four weeks ahead of the December 28 PDUFA date, Cantor Fitzgerald analyst Elemer Piros raised his price target on Ocular shares to $24 from $22. He believes all manufacturing related issues have been addressed, adding that the upgraded manufacturing processes bode well for the company's entire platform. Piros maintains an Overweight rating on Ocular Therapeutix shares.
NFLX Netflix
$324.77

4.81 (1.50%)

01/07/19
PIPR
01/07/19
NO CHANGE
Target $430
PIPR
Overweight
Netflix search index indicates 'strong' U.S. subs in Q4, says Piper Jaffray
Piper Jaffray analyst Michael Olson says his analysis of Netflix search trends points to a "strong" Q4 for domestic subscribers, with international likely in-line. Consensus calls for 10.0% year-over-year domestic sub growth in Q4 and Piper's search index points to 11.5% growth, Olson tells investors in a research note. For international, Q4 consensus calls for 36.7% year-over-year sub growth and Piper's index points to 46.0% growth, adds the analyst. Olson keeps an Overweight rating on Netflix shares with a $430 price target.
01/04/19
01/04/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Intel (INTC) upgraded to Buy from Neutral at BofA/Merrill with analyst Vivek Arya saying the stock provides attractive exposure to growth trends in cloud computing, AI, advanced autos and 5G. 2. Netflix (NFLX) upgraded to Conviction Buy from Buy at Goldman Sachs with analyst Heath Terry saying with the stock down 36% since record highs in July, Netflix represents one of the best risk/reward propositions in the Internet sector. 3. Shutterfly (SFLY) upgraded to Overweight from Sector Weight at KeyBanc with analyst Edward Yruma saying valuation is "compelling" despite concerns about the promotional environment that have materialized. 4. Honeywell (HON) upgraded to Outperform from Sector Perform at RBC Capital with analyst Deane Dray saying the company looks to be benefiting from the re-rating that follows the Garrett/Resideo spins. 5. Etsy (ETSY) upgraded to Buy from Neutral at Goldman Sachs with analyst Heath Terry saying consensus estimates remain too low for 2019 as the company optimizes the incremental growth investments made possible by the take rate increase instituted in July 2018. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/10/19
UBSW
01/10/19
UPGRADE
UBSW
Buy
Netflix upgraded to Buy from Neutral at UBS
01/07/19
LEHM
01/07/19
NO CHANGE
Target $375
LEHM
Overweight
Netflix price target lowered to $375 from $430 at Barclays
Barclays analyst Kannan Venkateshwar lowered his price target for Netflix to $375 to reflect reduced multiples despite his "continued confidence in the underlying story." The analyst keeps an Overweight rating on the shares. Netflix has outlined a strategy of releasing 90 movies every year, which would make it the second-biggest movie studio after Disney in terms of production budgets, Venkateshwar tells investors in a research note titled "Films need an offline strategy." The analyst believes Netflix could see greater benefit from a more nuanced distribution strategy than a "one size fits all" approach. Franchise-oriented films will need to include theatrical release on a larger scale to optimize returns, says Venkateshwar.
LEN Lennar
$45.17

-1.14 (-2.46%)

01/10/19
RBCM
01/10/19
NO CHANGE
Target $53
RBCM
Outperform
Lennar price target lowered to $53 from $58 at RBC Capital
RBC Capital analyst Mike Dahl lowered his price target on Lennar to reflect the impact of the "sales of Rialto and parts of financial services" along with the "core weakness in orders and margins." The analyst keeps his Outperform rating however, noting that the valuation on Lennar shares remains reasonable while also citing the market's willingness to look past the near term weakness after the stock rallied on a worse Q1 pre-announcement.
01/10/19
DBAB
01/10/19
NO CHANGE
Target $56
DBAB
Buy
Lennar price target raised to $56 from $51 at Deutsche Bank
Deutsche Bank analyst Nishu Sood raised his price target for Lennar to $56 saying the company's Q4 results show "steady through the storm." The analyst believes the stock's rally on the operating flexibility that Lennar has demonstrated through "this period of turmoil" makes sense. He keeps a Buy rating on the shares.
01/07/19
KEYB
01/07/19
UPGRADE
KEYB
Overweight
Lennar upgraded to Overweight from Sector Weight at KeyBanc
01/07/19
01/07/19
UPGRADE

Overweight
Lennar upgraded to Overweight at KeyBanc
As previously reported, KeyBanc analyst Kenneth Zener upgraded Lennar to Overweight from Sector Weight, with a $50 price target, as he expects the stock, at 1.1 times FY19 book, to provide valuation support. Though he believes Builder estimates in general are more prone to downward revisions, the Builders' valuation history shows resiliency despite negative data trends in past inflection cycles. Given Lennar's still ongoing acquisition of CalAtlantic, and with results still pro forma and including purchase accounting, Zener expects positive management comments.
GLUU Glu Mobile
$9.10

0.21 (2.36%)

11/07/18
PIPR
11/07/18
NO CHANGE
Target $8
PIPR
Overweight
Glu Mobile target raised to $8 on 'strong' Q3 at Piper Jaffray
Piper Jaffray analyst Michael Olson raised his price target for Glu Mobile to $8 from $7.50 citing the company's "strong" Q3 results with bookings and adjusted EBITDA ahead of Street expectations. Glu Mobile is positioned for a "favorable ongoing trajectory," with management reducing dependence on new and celebrity content, along with improving revenue visibility and cost containment, Olson tells investors in a post-earnings research note. He sees a path to multiple expansion and margin improvement and keeps an Overweight rating on Glu Mobile.
01/10/19
SPHN
01/10/19
INITIATION
Target $10.5
SPHN
Overweight
Glu Mobile initiated with an Overweight at Stephens
Stephens analyst Jeff Cohen initiated coverage of the video game sector, starting Glu Mobile with an Overweight rating and $10.50 price target. Glu has successfully transformed itself and he is bullish on the slate of 3 games that it has planned for the second half of 2019, Cohen tells investors.
10/22/18
PIPR
10/22/18
NO CHANGE
PIPR
Teen survey positive for console publisher group, says Piper Jaffray
Piper Jaffray analyst Michael Olson says his firm's 36th semi-annual survey of 8,600 teens shows that video game console ownership was up, with 83% claiming to own a current gen console or expecting to buy one. Spending on video games also increased, from 13% of male teen budgets in spring 2018 to 14% currently, Olson tells investors in a research note. Further, he points out that a growing number of teens watch others play games via YouTube and Twitch, while the number of teens who play mobile games fell from the spring survey. The analyst views the data as positive for the console publisher group Activision Blizzard (ATVI), Electronic Arts (EA) and Take-Two (TTWO), and neutral for mobile game companies Zynga (ZNGA) and Glu Mobile (GLUU).
12/10/18
COWN
12/10/18
NO CHANGE
Target $9.5
COWN
Outperform
Glu Mobile price target raised to $9.50 from $8 at Cowen
Cowen analyst Doug Creutz maintained an Outperform rating on Glu Mobile and raised his price target to $9.50, telling investors in a research note that Glu is his Best Idea for 2019. In a research note to investors, Creutz says execution on the core business has been "excellent" for the last two years, the company has an exciting 2019 product pipeline, and valuation remains reasonable given significant earnings leverage against expected revenue growth.
ATVI Activision Blizzard
$51.35

0.52 (1.02%)

01/02/19
RHCO
01/02/19
NO CHANGE
Target $65
RHCO
Buy
Activision Blizzard CFO transition to be 'fairly seamless', says SunTrust
SunTrust analyst Matthew Thornton kept his Buy rating and $65 price target on Activision Blizzard (ATVI) after the departure of its CFO Spencer Neumann to Netflix (NFLX). The analyst notes that the company's current Chief Corporate Officer Dennis Durkin is expected to step back into the CFO role which he has previously filled for over 5 years. Thornton expects that transition to be "fairly seamless" and without any business disruption given Durkin's history in the management team and his investor appeal.
01/03/19
BNCH
01/03/19
NO CHANGE
BNCH
Activision, Canopy Growth among Best Ideas for first half of 2019 at Benchmark
Benchmark analysts selected their Best Ideas for the first half of 2019, naming 16 stocks, including: Activision Blizzard (ATVI), BioTelemetry (BEAT), Biofrontera (BFRA), Ctrip (CTRP), Huazhu Group (HTHT), II-VI (IIVI), Intevac (IVAC), LHC Group (LHCG), Meredith (MDP), Marvell (MRVL), NeoGenomics (NEO), Pegasystems (PEGA), Silicon Labs (SLAB), Varonis (VRNS), Canopy Growth (CGC) and Waitr Holdings (WTRH).
01/10/19
SPHN
01/10/19
INITIATION
Target $65
SPHN
Overweight
Activision Blizzard initiated with an Overweight at Stephens
Stephens analyst Jeff Cohen initiated coverage of the video game sector, starting Activision Blizzard with an Overweight rating and $65 price target. He calls Activision "the most diversified publisher across all 3 gaming platforms" and views the stock as the best way for investors to play the growth of esports, Cohen tells investors.
01/04/19
MSCO
01/04/19
NO CHANGE
Target $75
MSCO
Equal Weight
Morgan Stanley 'optimistic' about Square choice of Ahuja as new CFO
After Square (SQ) announced that Amrita Ahuja, currently the CFO of Activision Blizzard's (ATVI) Blizzard Entertainment unit, will be its new CFO starting this month, Morgan Stanley analyst James Faucette said he is "optimistic" about the choice and view the news as positive. He noted that Square's prior CFO, Sarah Friar, was instrumental in managing expectations while also articulating the company's long-term opportunities, but he thinks Ahuja's diverse experience should help her as she becomes a key strategy decisionmaker and communicator to the Street. Faucette maintains his Equal Weight rating on Square shares with a $75 price target.
SDLP Seadrill Partners
$1.88

-0.07 (-3.59%)

URBN Urban Outfitters
$32.56

-1.2 (-3.55%)

01/09/19
MSCO
01/09/19
NO CHANGE
MSCO
Morgan Stanley says Amazon may be near ceiling with current apparel offering
Morgan Stanley analyst Kimberly Greenberger reports that the firm's apparel survey showed that 72% of consumers purchased apparel on Amazon (AMZN) in the past 6 months, up from 69% last year. While this suggests Amazon continues to take apparel market share, the fact that the figure had jumped by 11% from 2016 to 2017 shows its gains may have slowed, said Greenberger, who noted that survey data and analysis suggest this may be due to Amazon seeing less success in fashion apparel versus its traction in apparel basics. Amazon ranked third lowest in terms of perception of offering "fashionable" clothing out of the more than 30 retailers surveyed, with only Walmart (WMT) and Costco (COST) ranked lower, noted Greenberger, who believes a lack of fashion success does not preclude Amazon from becoming the number one apparel market share player but could limit its long-term share gains. The fact that fashion "may be a more difficult code to crack" may also mean that traditional apparel retailers who lead in fashion credibility or low-price can better survive long-term, added the analyst. As previously reported, Greenberger upgraded Urban Outfitters (URBN) to Overweight this morning, in part due to its "fashion authority."
01/09/19
MSCO
01/09/19
UPGRADE
MSCO
Overweight
Urban Outfitters upgraded to Overweight from Equal Weight at Morgan Stanley
01/07/19
01/07/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Skyworks (SWKS) downgraded to Perform from Outperform at Oppenheimer with analyst Rick Schafer citing the current "semiconductor correction" as well as "continued negative" smartphone news. 2. Snap (SNAP) downgraded to Hold from Buy at Pivotal Research with analyst Brian Wieser saying concerns around employee churn are playing out. 3. PNC Financial (PNC) downgraded to Neutral from Buy at Goldman Sachs with analyst Richard Ramsden saying commercial loan growth has fallen 7 percentage points and is likely to track industry growth rates more closely from here. 4. Quarterhill (QTRH) downgraded to Hold from Buy at Canaccord. 5. Urban Outfitters (URBN) downgraded to Neutral from Overweight at JPMorgan with analyst Matthew Boss saying he sees a "flattish comp downside scenario neutralizing the risk/reward profile." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/09/19
01/09/19
UPGRADE
Target $44

Overweight
Morgan Stanley upgrades Urban Outfitters to Overweight on fashion shift
As previously reported, Morgan Stanley analyst Kimberly Greenberger upgraded Urban Outfitters to Overweight from Equal Weight, stating that she would use the 23% pullback since the end of Q3 as an entry point into the stock. The current fashion shift looks to be at an early stage and favors Urban's brands more than its specialty peers, according to Greenberger. Morgan Stanley's recent polling of 2,000 teens and adults to determine apparel purchase drivers and future intentions support Urban's fashion credibility, noted the analyst. Additionally, the fast supply chain bolsters Urban's merchandising strategy and she expects inventory best practices to support merchandise margins at all three of its brands, Greenberger said. She maintains a $44 price target on Urban Outfitters shares.

TODAY'S FREE FLY STORIES

SRNE

Sorrento Therapeutics

$2.30

0.04 (1.77%)

07:23
01/22/19
01/22
07:23
01/22/19
07:23
Hot Stocks
Sorrento Therapeutics announces interim RTX study data »

Sorrento Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LXRX

Lexicon

$5.96

-1.73 (-22.50%)

, SNY

Sanofi

$41.50

-0.54 (-1.28%)

07:23
01/22/19
01/22
07:23
01/22/19
07:23
Recommendations
Lexicon, Sanofi analyst commentary  »

Lexicon price target…

LXRX

Lexicon

$5.96

-1.73 (-22.50%)

SNY

Sanofi

$41.50

-0.54 (-1.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 28

    Jan

  • 11

    Mar

  • 22

    Mar

  • 28

    Apr

FTNT

Fortinet

$70.50

-2.1 (-2.89%)

07:22
01/22/19
01/22
07:22
01/22/19
07:22
Downgrade
Fortinet rating change  »

Fortinet downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 06

    Feb

  • 25

    Feb

ATI

Allegheny Technologies

$25.48

0.5 (2.00%)

07:22
01/22/19
01/22
07:22
01/22/19
07:22
Earnings
Allegheny Technologies reports Q4 EPS 30c, consensus 34c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

IRMD

iRadimed

$25.77

0.32 (1.26%)

07:21
01/22/19
01/22
07:21
01/22/19
07:21
Hot Stocks
iRadimed suspends sales of 3880 patient vital signs monitoring system »

iRadimed announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AINV

Apollo Investment

$14.51

-0.01 (-0.07%)

07:19
01/22/19
01/22
07:19
01/22/19
07:19
Upgrade
Apollo Investment rating change  »

Citi upgrades Apollo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

FITB

Fifth Third

$27.00

0.59 (2.23%)

, MBFI

MB Financial

$44.59

0.83 (1.90%)

07:19
01/22/19
01/22
07:19
01/22/19
07:19
Hot Stocks
Fifth Third sees FY19 NII up approx. 3% from FY18 »

Sees Q1 NII down 1.5%-2%…

FITB

Fifth Third

$27.00

0.59 (2.23%)

MBFI

MB Financial

$44.59

0.83 (1.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

ICE

IntercontinentalExchange

, CME

CME Group

$183.47

2.25 (1.24%)

07:18
01/22/19
01/22
07:18
01/22/19
07:18
Recommendations
IntercontinentalExchange, CME Group analyst commentary  »

Citi upgrades ICE to Buy,…

ICE

IntercontinentalExchange

CME

CME Group

$183.47

2.25 (1.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

  • 08

    May

  • 28

    May

MO

Altria Group

$48.29

1.22 (2.59%)

, PM

Philip Morris

$73.77

1.25 (1.72%)

07:18
01/22/19
01/22
07:18
01/22/19
07:18
Downgrade
Altria Group, Philip Morris rating change  »

Altria Group downgraded…

MO

Altria Group

$48.29

1.22 (2.59%)

PM

Philip Morris

$73.77

1.25 (1.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

  • 07

    Feb

  • 18

    Feb

AUPH

Aurinia Pharmaceuticals

$7.54

0.11 (1.48%)

, AGN

Allergan

$160.28

3.74 (2.39%)

07:16
01/22/19
01/22
07:16
01/22/19
07:16
Periodicals
Aurinia CEO says VOS could become blockbuster treatment, STATNews reports »

Though Aurinia…

AUPH

Aurinia Pharmaceuticals

$7.54

0.11 (1.48%)

AGN

Allergan

$160.28

3.74 (2.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 29

    Jan

  • 18

    May

  • 28

    May

AMZN

Amazon.com

$1,696.01

4.01 (0.24%)

07:14
01/22/19
01/22
07:14
01/22/19
07:14
Recommendations
Amazon.com analyst commentary  »

Amazon.com remains…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 31

    Jan

  • 20

    Feb

  • 03

    Mar

CRSP

Crispr Therapeutics

$37.21

1.22 (3.39%)

07:14
01/22/19
01/22
07:14
01/22/19
07:14
Hot Stocks
Crispr Therapeutics signs collaboration agreement with ProBioGen »

Crispr Therapeutics and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STZ

Constellation Brands

$164.13

3.78 (2.36%)

07:13
01/22/19
01/22
07:13
01/22/19
07:13
Initiation
Constellation Brands initiated  »

Constellation Brands…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

HBM

Hudbay Minerals

$5.65

0.03 (0.53%)

07:12
01/22/19
01/22
07:12
01/22/19
07:12
Downgrade
Hudbay Minerals rating change  »

Hudbay Minerals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

CRSP

Crispr Therapeutics

$37.21

1.22 (3.39%)

07:12
01/22/19
01/22
07:12
01/22/19
07:12
Downgrade
Crispr Therapeutics rating change  »

Citi downgrades Crispr…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BTE

Baytex Energy

$1.92

-0.05 (-2.54%)

07:12
01/22/19
01/22
07:12
01/22/19
07:12
Downgrade
Baytex Energy rating change  »

Baytex Energy downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Feb

FB

Facebook

$150.01

1.77 (1.19%)

07:11
01/22/19
01/22
07:11
01/22/19
07:11
Periodicals
VC says Facebook the most 'vulnerable' big tech firm, CNBC reports »

Facebook is the most…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 30

    Jan

  • 25

    Feb

  • 03

    Mar

PEBO

Peoples Bancorp

$31.57

-0.11 (-0.35%)

07:11
01/22/19
01/22
07:11
01/22/19
07:11
Hot Stocks
Peoples Bancorp reports Q4 net interest margin 3.77% vs. 3.68% sequentially »

Compared to 3.63% for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

AXGN

AxoGen

$16.00

0.64 (4.17%)

07:10
01/22/19
01/22
07:10
01/22/19
07:10
Hot Stocks
AxoGen appoints Eric Sandberg CCO »

AxoGen (AXGN) announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PEBO

Peoples Bancorp

$31.57

-0.11 (-0.35%)

07:10
01/22/19
01/22
07:10
01/22/19
07:10
Earnings
Peoples Bancorp reports Q4 EPS 71c, consensus 67c »

Earnings per diluted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

CTSO

CytoSorbents

$7.66

0.04 (0.52%)

07:09
01/22/19
01/22
07:09
01/22/19
07:09
Hot Stocks
CytoSorbents expands partnership with Fresenius Medical Care to Korea and Mexico »

CytoSorbents announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WB

Weibo

$60.80

2.57 (4.41%)

07:09
01/22/19
01/22
07:09
01/22/19
07:09
Downgrade
Weibo rating change  »

Weibo downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DRNA

Dicerna

$10.76

-0.395 (-3.54%)

07:08
01/22/19
01/22
07:08
01/22/19
07:08
Upgrade
Dicerna rating change  »

Dicerna upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRV

Travelers

$123.97

1.03 (0.84%)

07:07
01/22/19
01/22
07:07
01/22/19
07:07
Hot Stocks
Travelers reports Q4 return on equity 10.9% »

Reports Q4 core return on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

VYGR

Voyager Therapeutics

$8.27

-0.22 (-2.59%)

, RHHBY

Roche

$0.00

(0.00%)

07:07
01/22/19
01/22
07:07
01/22/19
07:07
Hot Stocks
Voyager Therapeutics names Robert Hesslein as general counsel »

Voyager Therapeutics…

VYGR

Voyager Therapeutics

$8.27

-0.22 (-2.59%)

RHHBY

Roche

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 01

    Feb

  • 18

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.